Influence of acute exposure to high altitude and hypoxemia on ventricular stimulation thresholds in pacemaker patients

Flight safety in patients with arrhythmia

As it is comfortable, fast, and safe, an increasing number of patients with heart disease prefer to travel by flight. However, there is not much information about the problems that patients with arrhythmia may experience during air travel. In addition, the precautions to be taken with these patients during a flight are uncertain. In this review, the management of patients with cardiac conduction problems during flight was examined in detail.

[Heart Patients and Exposure to Altitude]

Overall, heart patients should be advised individually with respect to their tolerance of altitudes. However, the historical reflex that altitude 'per se' is bad for heart patients should become a thing of the past. Adequately treated and stable patients can usually go up to an altitude of 2500 m without any restrictions. Higher altitudes are also possible for a large number of patients, but may require an adaptation of the medication and further clarification. This is especially the case when physical work is to be performed at great heights.

Commercial Air Travel for Passengers With Cardiovascular Disease: Stressors of Flight and Aeromedical Impact

The exponential growth of commercial flights has resulted in a sharp rise of air travellers over the last 2 decades, including passengers with a wide range of cardiovascular conditions. Notwithstanding the ongoing COVID-19 pandemic that had set back the aviation industry for the next 1 to 2 years, air travel is expected to rebound fully by 2023-2024. Guidelines and evidence-based recommendations for safe air travel in this group vary, and physicians often encounter situations where opinions and assessments on fitness for flights are sought. This article aims to provide an overview of the stressors of commercial passenger flights with an impact on cardiovascular health for the general cardiologist and family practitioner, when assessing the suitability of such patients for flying fitness.

Clinical recommendations for high altitude exposure of individuals with pre-existing cardiovascular conditions: A joint statement by the European Society of Cardiology, the Council on Hypertension of the European Society of Cardiology, the European Society of Hypertension, the International Society of Mountain Medicine, the Italian Society of Hypertension and the Italian Society of Mountain Medicine

Take home figure

[Travelling with a pacemaker or implanted defibrillator]

There are no guidelines for patients travelling with implanted pacemakers or defibrillators. Only few publications deal with specific problems that this patient group might face. In this article different aspects of travelling with implanted electric devices are summarized. Patients with pacemakers and implanted defibrillators have nearly no limits when travelling. An exception to that rule is scuba diving, which mostly is limited because of the device. In general it is the underlying heart disease or arrhythmia that limits patients' travel activities. It is reasonable to travel after implantation only after wound healing is complete because arm movement on the implant site is limited and the risk of wound infection and lead dislocation is elevated in the early phase. However, if necessary, flying is possible 2 days after an uncomplicated implantation if pneumothorax can be excluded. Security checks can be passed safely by patients with pacemakers/defibrillators. Only repetitive movement of a handheld metal detector over the device should be avoided. When travelling to different time zones it might be reasonable to deactivate a programmed sleep rate (Medtronic, Biotronik). Patients at risk for ventricular arrhythmia (mainly patients with an implantable cardioverter-defibrillator) must make sure to take all possible preventive measures to avoid travelers' diarrhea. In case of infection early replacement of fluids and electrolytes is essential.

Navigating air travel and cardiovascular concerns: Is the sky the limit?

As the population ages and our ability to care for patients with cardiac disease improves, an increasing number of passengers with cardiovascular conditions will be traveling long distances. Many have had cardiac symptoms, recent interventions, devices, or surgery. Air travel is safe for most individuals with stable cardiovascular disease. However, a thorough understanding of the physiologic changes during air travel is essential given the potential impact on cardiovascular health and the risk of complications in passengers with preexisting cardiac conditions. It is important for clinicians to be aware of the current recommendations and precautions that need to be taken before and during air travel for passengers with cardiovascular concerns.

Altitude and the heart: is going high safe for your cardiac patient?

Our aging population combined with the ease of travel and the interest in high altitude recreation pursuits exposes more patients to the acute physiologic effects of high altitude and lower oxygen availability. Acute exposure to high altitude is associated with significant alterations to the cardiovascular system. These may be important in patients with underlying cardiovascular disease who are not able to compensate to such physiologic changes. Exacerbating factors pertinent to patients with cardiovascular disease include acute hypoxia, increased myocardial work, increased epinephrine release, and increased pulmonary artery pressures. This review summarizes the physiology and clinical evidence regarding acute altitude exposure on the cardiopulmonary system with practical recommendations to address the question: "Is it safe for me to ski in the Rockies or climb Mt. Kilimanjaro?"

Do daily threshold trend fluctuations of epicardial leads correlate with pacing and sensing characteristics in paediatric patients?

AIMS

To evaluate whether the magnitude of daily ventricular pacing threshold fluctuations (Deltafluctuation) in trend graphs of stored diagrams correlate with ventricular threshold and sensing changes over time.

METHODS AND RESULTS

A total of 56 children received AutoCapture devices (St. Jude Medical, Sylmar, CA, USA) connected to steroid-eluting epicardial leads. Maximum lead age at study closure was 12.2 years (median 4.0). Telemetry data and daily Deltafluctuation were obtained every 6 months. Regression slope coefficients and mean values of repeated measurements were calculated for each patient's course. High daily Deltafluctuation correlated with higher pacing thresholds (rho = 0.68, P < 0.001), lower impedances (rho = -0.38, P = 0.004), and a Deltafluctuation-incline (rho = 0.34, P = 0.01) over time. Furthermore, a Deltafluctuation-incline correlated with a pacing threshold-incline (rho = 0.34, P = 0.01). No correlation was observed for ventricular sensing. Higher daily Deltafluctuation were observed if lead age was > 5 years compared with <or= 5 years (0.75 vs. 0.55 V@0.5 ms, P = 0.028).

CONCLUSION

High amplitudes of daily Deltafluctuation correlate with higher and increasing pacing thresholds and lower impedances. Theoretically, this results from electrode microinstability on the epicardial surface. A decrease of the steroid-eluting potency of the electrode can be hypothesized to cause higher daily Deltafluctuation beyond a lead age of 5 years. Potential implications of marked daily Deltafluctuation are short-term follow-up and lead replacement in the presence of high pacing thresholds.

Working in permanent hypoxia for fire protection-impact on health

OBJECTIVES

A new technique to prevent fires is continuous exchange of oxygen with nitrogen which leads to an oxygen concentration of between 15% and 13% in the ambient air. This paper reviews the effect of short-term, intermittent hypoxia on health and performance of people working in such atmospheres.

METHODS

We reviewed the effect of ambient air hypoxia on human health in the literature using Medline, as well as reference lists of articles and handbooks. Articles were assessed from the perspective of working conditions in fire-protected rooms.

RESULTS

Oxygen reduced to 15% and 13% in normobaric atmospheres is equivalent to the hypobaric atmospheres found at 2,700 and 3,850-m altitudes. When acutely exposed, a healthy person responds within minutes to hours with increased ventilation, stimulation of the sympathetic system, increased heart rate, increased pulmonary-circulation resistance, reduced plasma volume, and stimulation of erythropoesis. Acute mountain sickness occurs frequently at these oxygen partial pressures, but the full syndrome is rare if continuous exposure is limited to 6 h. Mood, cognitive, and psychomotor functions may be mildly impaired in these conditions, but data are inconclusive. Persons suffering from cardiac, pulmonary, or hematological diseases should consult a specialist in order for their individual risk to be assessed, and medical screening for any of these diseases is strongly recommended prior to exposure.

CONCLUSION

Preliminary evidence suggests that working environments with low oxygen concentrations to a minimum of 13% and normal barometric pressure do not impose a health hazard, provided that precautions are observed, comprising medical examinations and limitation of exposure time. However, evidence is limited, particularly with regard to workers performing strenuous tasks or having various diseases. Therefore, close monitoring of the health problems of people working in low oxygen atmospheres is necessary.

The impact of automatic threshold tracking on pulse generator longevity in patients with different chronic stimulation thresholds

Automatic adjustment of the stimulation output of pacemakers to changing stimulation thresholds using the Autocapture feature increases patient safety and decreases energy consumption. This study examined the impact of Autocapture on pulse generator longevity in patients with different chronic stimulation thresholds. Eighty patients (mean age 79 +/- 9 years; 37 men, 43 women) with Pacesetter Regency SR+ pacemakers were included in the study. Data were collected before discharge of the patients from the hospital, 6-12 weeks postimplant, and then every 6-12 months. Pulse generator longevity was calculated theoretically, assuming 100% stimulation with a stable threshold, at a pacing rate of 65 +/- 6 beats/min and 1% backup pulses. Theoretical pulse generator longevity was calculated for low (< 1 V), intermediate (> or = 1 V and < 2 V), and high (> or = 2 V) stimulation thresholds. Pulse generator longevity was compared among three groups: (A) Autocapture programmed On, (B) Autocapture programmed Off, (C) theoretical calculations using thresholds of patients in group A with the stimulation voltage programmed at twice pacing threshold, or at a minimum of 2.4 V. The mean follow-up time since implantation was 19 +/- 8 months. The calculated longevity benefits for patients in group A were 36%, 59%, and 30% compared to group B, and 19%, 32%, and 49% compared to group C in patients with low, intermediate, and high chronic stimulation thresholds, respectively. Theoretical calculations based on chronic stimulation thresholds in our patient population with Regency SR+ pacemakers suggest that Autocapture may markedly prolong pulse generator longevity in patients with a broad range of long-term pacing thresholds.

Threshold tracking pacing based on beat by beat evoked response detection: clinical benefits and potential problems

Continuous monitoring of pacemaker stimulation thresholds and automatic adjustment of pacemaker outputs were among the longstanding goals of the pacing community. The first clinically successful implementation of threshold tracking pacing was the Autocapture feature which has accomplished automatic ventricular capture verification for every single stimulus by monitoring the Evoked Response (ER) signal resulting from myocardial depolarization. The Autocapture feature not only decreases energy consumption by keeping the stimulation output slightly above the actual threshold, but also increases patient safety by access to high-output back-up pulses if there is loss of capture. Furthermore, it provides valuable documentation of stimulation thresholds over time and serves as a valuable research tool. Current limitations for its widespread use include the requirements for implantation of bipolar low polarization leads and unipolar pacing in the ventricle. Fusion/pseudofusion beats with resultant insufficient or even non-existent ER signal amplitudes followed by unnecessary delivery of back-up pulses and a possible increase in pacemaker output is not an uncommon observation unique to the Autocapture feature. The recent incorporation of the Autocapture algorithm in dual chamber pacemakers has been challenging because of more frequent occurrence of fusion/pseudofusion beats in the presence of normal AV conduction. Along with a review of the previously published studies and our clinical experience, this article discusses the clinical advantages and potential problems of Autocapture.